About: Intracellular human antibody fragments recognizing the VP35 protein of Zaire Ebola filovirus inhibit the protein activity

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Intracellular human antibody fragments recognizing the VP35 protein of Zaire Ebola filovirus inhibit the protein activity Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Intracellular human antibody fragments recognizing the VP35 protein of Zaire Ebola filovirus inhibit the protein activity
Creator	Ascione, Alessandro Di Bonito, Paola Flego, Michela Tramontano, Enzo Vella, Stefano Accardi, Luisa Fanunza, Elisa Frau, Aldo Gellini, Mara Mallano, Alessandra
Source	Medline; PMC
abstract	BACKGROUND: Ebola hemorrhagic fever is caused by the Ebola filovirus (EBOV), which is one of the most aggressive infectious agents known worldwide. The EBOV pathogenesis starts with uncontrolled viral replication and subversion of both the innate and adaptive host immune response. The multifunctional viral VP35 protein is involved in this process by exerting an antagonistic action against the early antiviral alpha/beta interferon (IFN-α/β) response, and represents a suitable target for the development of strategies to control EBOV infection. Phage display technology permits to select antibodies as single chain Fragment variable (scFv) from an artificial immune system, due to their ability to specifically recognize the antigen of interest. ScFv is ideal for genetic manipulation and to obtain antibody constructs useful for targeting either antigens expressed on cell surface or intracellular antigens if the scFv is expressed as intracellular antibody (intrabody) or delivered into the cells. RESULTS: Monoclonal antibodies (mAb) in scFv format specific for the EBOV VP35 were isolated from the ETH-2 library of human recombinant antibodies by phage display technology. Five different clones were identified by sequencing, produced in E.coli and expressed in CHO mammalian cells to be characterized in vitro. All the selected scFvs were able to react with recombinant VP35 protein in ELISA, one of the scFvs being also able to react in Western Blot assay (WB). In addition, all scFvs were expressed in cell cytoplasm as intrabodies; a luciferase reporter gene inhibition assay performed in A549 cells showed that two of the scFvs can significantly hamper the inhibition of the IFN-β-induced RIG-I signaling cascade mediated by EBOV VP35. CONCLUSION: Five antibodies in scFv format recognize an active form of EBOV VP35 in ELISA, while one antibody also recognizes VP35 in WB. Two of these scFvs were also able to interfere with the intracellular activity of VP35 in a cell system in vitro. These findings suggest that such antibodies in scFv format might be employed to develop therapeutic molecules able to hamper EBOV infections.
has issue date	2019-09-05(xsd:dateTime)
bibo:doi	10.1186/s12896-019-0554-2
bibo:pmid	31488108
has license	cc-by
sha1sum (hex)	a0797dceb80b7f1c136590f3ba4b16da218de23f
schema:url	https://doi.org/10.1186/s12896-019-0554-2
resource representing a document's title	Intracellular human antibody fragments recognizing the VP35 protein of Zaire Ebola filovirus inhibit the protein activity
has PubMed Central identifier	PMC6727353
has PubMed identifier	31488108
schema:publication	BMC Biotechnol
resource representing a document's body	covid:a0797dceb80b7f1c136590f3ba4b16da218de23f#body_text
is schema:about of	named entity 'PROTEIN ACTIVITY' named entity 'surface' named entity 'Monoclonal antibodies' named entity 'scFv' named entity 'EBOV' named entity 'permits' named entity 'ScFv' named entity 'E.coli' named entity 'viral' named entity 'filovirus' named entity 'ABILITY TO' covid:arg/a0797dceb80b7f1c136590f3ba4b16da218de23f named entity 'SELECT' named entity 'HAMPER' named entity 'ACTION' named entity 'SUITABLE' named entity 'EITHER' named entity 'OBTAIN' named entity 'EARLY' named entity 'RESULTS' named entity 'EBOLA HEMORRHAGIC FEVER' named entity 'THEIR' named entity 'CLONES' named entity 'CYTOPLASM' named entity 'USEFUL' named entity 'FILOVIRUS' named entity 'RIG-I' named entity 'AGGRESSIVE' named entity 'CHARACTERIZED' named entity 'LUCIFERASE' named entity 'SPECIFIC' named entity 'STRATEGIES' named entity 'INTRACELLULAR' named entity 'INFECTION' named entity 'RECOMBINANT' named entity 'PROCESS' named entity 'IFN' named entity 'ALPHA' named entity 'PERFORMED' named entity 'CELLS' named entity 'ANTIGENS' named entity 'SIGNALING CASCADE' named entity 'MEDIATED' named entity 'HOST IMMUNE RESPONSE' named entity 'SCFV' named entity 'VIRAL REPLICATION' named entity 'CELL' named entity 'INHIBITION' named entity 'ISOLATED' named entity 'KNOWN' named entity 'ADAPTIVE' named entity 'CELL SURFACE' named entity 'ANTIBODY' named entity 'VP35' named entity 'PROTEIN ' named entity 'WORLDWIDE' named entity 'RECOGNIZE' named entity 'SINGLE' named entity 'UNCONTROLLED' named entity 'BACKGROUND' named entity 'MONOCLONAL ANTIBODIES' named entity 'RECOMBINANT ANTIBODIES' named entity 'ANTIBODY' named entity 'TO CONTROL' named entity 'EXPRESSED' named entity 'A549 CELLS' named entity 'IDEAL' named entity 'IDENTIFIED BY' named entity 'REACT' named entity 'REPORTER GENE' named entity 'HUMAN' named entity 'ZAIRE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software